Defence Therapeutics (DTCFF) Stock Price, News & Analysis

Company Overview

Defence Therapeutics Inc. is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer. The company’s proprietary AccuTOX™ platform leverages antibody–drug conjugate (ADC) technology designed to deliver cytotoxic agents directly to tumor cells while minimizing off-target effects. Defence Therapeutics’ approach is intended to enhance the selectivity and efficacy of cancer treatments by combining tumor-specific binding with potent drug payloads.

The company’s pipeline includes multiple ADC candidates in preclinical and early clinical development, targeting a range of solid tumors. Each candidate is engineered to recognize tumor-associated antigens and to induce a robust cytotoxic response upon internalization. Defence Therapeutics continues to advance its lead programs through regulatory interactions and patient enrollment initiatives, with the goal of demonstrating safety and preliminary efficacy in first-in-human trials.

Headquartered in Montreal, Quebec, Defence Therapeutics engages in research collaborations with academic partners and contract research organizations to accelerate its discovery and development efforts. The company maintains a management team with expertise in oncology drug development, regulatory affairs and clinical operations, and pursues strategic alliances to expand its technology platform and advance novel immunotherapeutic candidates toward commercialization.

Key Stats

• Today's Range: $0.52 to $0.52
• 50-Day Range: $0.52 to $0.76
• 52-Week Range: $0.27 to $1.16
• Volume: N/A
• Average Volume: 15,603 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DTCFF Stock Analysis - Frequently Asked Questions

How have DTCFF shares performed this year?

Defence Therapeutics' stock was trading at $0.3901 at the beginning of the year. Since then, DTCFF shares have increased by 32.4% and is now trading at $0.5166.

How do I buy shares of Defence Therapeutics?

Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DTCFF
• CIK: N/A
• Web: defencetherapeutics.com
• Phone: 514 947 2272
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A